Transforming Drug Discovery
with AI-Enabled Multiomics
An AI-enabled precision medicine biotech company
for complex diseases
Dysregulation in the gut microbiome has been closely linked to a wide range of diseases.
Piton’s advanced discovery and development capabilities have propelled the company into a leadership position in the development of precision, small molecule, therapeutics targeting pathogenic pathways in the gut microbiome.
Our disease areas
Inflammatory
Ulcerative Colitis
5M
Global Cases
>2M
Eligible Patients
>20%
Bowel Resection Rate
~50%
Efficacy of Current Drugs
Ulcerative Colitis (UC) is a chronic inflammatory bowel disease characterized by inflammation of the colon's lining. There is no cure for UC. Approximately 30% of UC patients are unresponsive to or cannot tolerate UC medications. 20% of UC patients will require one or more surgical interventions. The cause of UC is unknown. Advanced UC therapeutics target inflammation, a primary symptom of UC, by restricting and/or suppressing the patient’s immune system.
Piton is the first therapeutic strategy to target a cause of UC. This orally dosed, gut-restricted, small molecule drug offers a new treatment paradigm for ~45% of UC patients – remission without compromising their immune system or unwanted side-effects.
Neurological
Autism
>55M
Eligible Patients
>70M
Global Cases
2.8%
US Children
1%
Humanity
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by difficulties in social communication and interaction, and the presence of restricted and repetitive behaviors, interests, or activities. There is no cure for ASD. There are no approved therapeutics to treat the core symptoms of ASD.
Piton’s lead candidate demonstrates significant restoration of socialization capabilities and a reduction in anxiety levels (a common cooccurring condition) in ASD animal models.
Metabolic
Diabetes
10M
Global Cases
~400M
Eligible Patients
<50%
Multi-morbidities
>1B
Obesity Prevalence
Approximately 520 million people have type-2 diabetes. There is no cure for this disease.
Piton’s novel therapeutic strategy seeks to reduce ambient blood glucose levels and improves systematic glucose tolerance by precisely targeting both human and microbial targets. Animal model experiments demonstrate lower average blood glucose levels than leading Diabetes medications.
Fathom Platform
Piton’s unique capabilities are realizing the untapped potential of microbiome-focused therapeutics. The company is a leader in the development of a new category of therapeutic modalities of orally delivered, small and large molecules that precisely target specific disease-causing mechanisms.
Discovery and drug development activities are efficiently and effectively facilitated by Piton’s proprietary Fathom Platform.
Fathom Platform technology
The Company’s novel and highly differentiated Fathom platform operates a technical stack in which analyzes multi-modal data and metadata acquired from clinical studies.
Precision drugs that target causal mechanisms in the gut microbiome.
Piton Therapeutics decodes microbiome signals to develop precision small molecule drugs for serious diseases with defined mechanisms of action. By translating microbiome insights into rationally designed therapeutics, we aim to transform patient care with novel, mechanism-driven treatments